Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: URGN

UroGen Pharma Ltd.

Healthcare | Biotechnology

No licensed closing price on file for URGN. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-1.97

UroGen Pharma Ltd. (NASDAQ: URGN) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 16:27 UTC.

What UroGen Pharma Ltd. does

This biotechnology company develops treatments for urothelial and specialty cancers using RTGel, a proprietary reverse-thermal hydrogel technology that remains liquid at cool temperatures and solidifies at body temperature. The company has commercialized two approved products: Jelmyto, a mitomycin formulation for low-grade upper tract urothelial cancer, and Zusduri, a mitomycin formulation for low-grade intermediate risk non-muscle invasive bladder cancer, both designed to treat tumors without surgery.

Summarized from UroGen Pharma Ltd.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-1.97

Revenue, margins & earnings

FY2021: net loss $111M on revenue $48M$48MFY2021FY2022: net loss $110M on revenue $64M$64MFY2022FY2023: net loss $102M on revenue $83M$83MFY2023FY2024: net loss $127M on revenue $90M$90MFY2024FY2025: net loss $153M on revenue $110M$110MFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-10-09
  • 2026-10-09Chief Financial OfficerSale-2,202$80.8K
  • 2026-10-09Chief Financial OfficerOption exercise4,483—
  • 2026-10-09Chief Financial OfficerRestricted Stock UnitsOption exercise-4,483—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does UroGen Pharma Ltd. do?

This biotechnology company develops treatments for urothelial and specialty cancers using RTGel, a proprietary reverse-thermal hydrogel technology that remains liquid at cool temperatures and solidifies at body temperature.

When did URGN last file with the SEC?

UroGen Pharma Ltd.'s most recent SEC filing on record is a 8-K filed 2026-06-23. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 16:27 UTC. This page is also available as JSON at /api/data?ticker=URGN and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for URGN and 5,000+ tickers.

Create a free account — keep URGN
For your agent
GET /api/data?ticker=URGN

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt